Biotek-snakken — September 2021
-
3 Top Healthcare Stocks to Buy for September
-
'It's game over. It's mRNA or nothing:' Expert on future of vaccines https://finance.yahoo.com/news/its-game-over-its-m-rna-or-nothing-expert-on-future-of-vaccines-200508222.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAM7dOhgASE4wmIpJqtc6TeOC8J6JKLZ7sZ35Fhj7ru1eO_U-qnIC8AohVYibAljwumlWdKoq3WCygD0iHceb-SUzKcMeL40qMGqXtxYYEDUXXS3eWrHaoDptdFycr4IVTG_HpHDvCuSVstpmPBtKKggnG1HQmNjEgvaYr7TJN4pj
-
Lassevedel - skrev til Sutro og de bekræftede det du også skrev, at STRO-003 bliver offentliggjort senere på året med timelines for IND. Desuden bekræftede de at STRO-003 bliver en af de nye targets, så mest oplagt er vel 5T4/CD3, da den synes længst fremme
-
Servicemeddelelse
Nu har Proinvestor løbende "updates reports on gurus" fra Validea i vort Nasdaq US newsfeed.
Validea er en investeringsforskningstjeneste, der følger de offentliggjorte strategier for investeringslegender. Validea tilbyder både aktieanalyse og modelporteføljer baseret på guruer, der har overgået markedet på lang sigt, herunder Warren Buffett, Benjamin Graham, Peter Lynch og Martin Zweig.
-
These Promising Clinical Results on Tezepelumab Could Be Huge for Amgen Investors https://www.proinvestor.com/investornyt/703071/these-promising-clinical-results-could-be-huge-for-amgen-investors
-
2 Top Biotech Stocks to Buy Right Now
https://www.proinvestor.com/investornyt/703119/2-top-biotech-stocks-to-buy-right-now -
Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress https://www.proinvestor.com/index.php?p=debat_1&postid=96966
-
BeiGene : FDA Accepts BLA For Tislelizumab In Esophageal Squamous Cell Carcinoma https://www.proinvestor.com/investornyt/703250/beigene-fda-accepts-bla-for-tislelizumab-in-esophageal-squamous-cell-carcinoma
-
Opdaterede GEA data fra Zymeworks: https://cslide.ctimeetingtech.com/esmo2021/attendee/con
fcal_4/presentation/list?q=zanidatamab -
-
Afbrudt vaccineaftale sender fransk biotekvirksomhed ned med 35 pct. https://www.proinvestor.com/investornyt/703270/afbrudt-vaccineaftale-sender-fransk-biotekvirksomhed-ned-med-35-pct
-
MiMedx: Phase 3 PF Study Fails To Meet Primary Endpoint; To Pursue Phase 3 KOA Confirmatory Studies https://www.proinvestor.com/investornyt/703340/mimedx-phase-3-pf-study-fails-to-meet-primary-endpoint-to-pursue-phase-3-koa-confirmatory-studies
-
AbbVie Inks Eye Care Deal With REGENXBIO https://www.proinvestor.com/investornyt/703341/abbvie-inks-eye-care-deal-with-regenxbio
-
Stock Market Alerts | MarketBeat
Read up-to-the-minute investing news with MarketBeat's instant stock market news alerts.
(www.marketbeat.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind